Date: Thursday, May 18, 2017
Session Type: Abstract Submissions
Session Time: 4:45PM-5:15PM
Methods: A retrospective review of prescriptions filled at NCH Specialty Pharmacy over a 4 month period assessed overall number of prescriptions, number of specialty prescriptions, patients enrolled, and MPR for adalimumab, etanercept, canakinumab, and tocilizumab. MPR was calculated for patients with >1 fills at NCH Specialty Pharmacy. An MPR of 1 reflects 100% adherence.
Results: In the first four months, NCH Specialty Pharmacy filled a total of 446 prescriptions and 132 specialty medications (adalimumab n=55; etanercept n=37; canakinumab n=19; tocilizumab n=11; other n=10) for 46 rheumatology patients. Average and median MPRs were assessed for adalimumab (0.95, 1) etanercept (0.95, 1), canakinumab (0.99, 1), and tocilizumab (1, 1), respectively. Overall, the average MPR was 0.96 and median MPR was 1.
Conclusion: The implementation of an institutional specialty pharmacy has added services to improve outcomes for children with rheumatic diseases. NCH was able to ensure a median MPR of 1 for all biologics filled at NCH Specialty Pharmacy during the pilot phase. It is expected that improvement in medication adherence will result in achievement of inactive disease. Strategies used by NCH Specialty Pharmacy to maintain an MPR of 1 include coordination of prior authorization, injection teaching by a pharmacist, and medication management consisting of monthly follow up with the patient or caregiver to schedule medication delivery. Rheumatologists at NCH will continue to enroll patients with JIA and other autoinflammatory diseases in NCH Specialty Pharmacy to ensure streamlined care and improved patient outcomes.
To cite this abstract in AMA style:Wise K, Lewis D, Thomas B, Jones K, Lemle S, MacDonald D, Barbar-Smiley F, Sivaraman V, Yildirim-Toruner C. Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/impact-of-an-institutional-specialty-pharmacy-on-adherence-to-biologic-therapies/. Accessed October 19, 2021.
« Back to 2017 Pediatric Rheumatology Symposium
ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-an-institutional-specialty-pharmacy-on-adherence-to-biologic-therapies/